Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Stereoselective disposition of proton pump inhibitors.

Andersson T, Weidolf L.

Clin Drug Investig. 2008;28(5):263-79. Review.

PMID:
18407713
2.

Enantioselective disposition of lansoprazole and rabeprazole in human plasma.

Miura M.

Yakugaku Zasshi. 2006 Jun;126(6):395-402. Review.

3.

Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.

Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T.

Eur J Clin Pharmacol. 2004 Nov;60(9):623-8. Epub 2004 Sep 23.

PMID:
15448955
4.

Enantioselective disposition of omeprazole, pantoprazole, and lansoprazole in a same Brazilian subjects group.

Cassiano NM, Oliveira RV, Bernasconi GC, Cass QB.

Chirality. 2012 Apr;24(4):289-93. doi: 10.1002/chir.21995. Epub 2012 Feb 17.

PMID:
22344845
5.

[New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].

de Korwin JD, Ducrotté P, Vallot T.

Presse Med. 2004 Jun 19;33(11):746-54. Review. French.

PMID:
15257232
6.

Recent advances in chirally pure proton pump inhibitors.

Pai V, Pai N.

J Indian Med Assoc. 2007 Aug;105(8):469-70, 472, 474. Review.

PMID:
18236913
8.

Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.

Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, Thorndike D, Wagner A, Chimalakonda A, Rodrigues AD.

Drug Metab Dispos. 2012 Sep;40(9):1698-711. doi: 10.1124/dmd.112.045575. Epub 2012 May 30.

9.
10.

Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.

Qiao HL, Hu YR, Tian X, Jia LJ, Gao N, Zhang LR, Guo YZ.

Eur J Clin Pharmacol. 2006 Feb;62(2):107-12. Epub 2006 Jan 10.

PMID:
16402242
11.

Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors?

Zhou Q, Yan XF, Pan WS, Zeng S.

World J Gastroenterol. 2008 Apr 28;14(16):2617-9.

13.

Pharmacokinetics of proton pump inhibitors in children.

Litalien C, Théorêt Y, Faure C.

Clin Pharmacokinet. 2005;44(5):441-66. Review.

PMID:
15871633
14.
15.

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.

Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T.

Aliment Pharmacol Ther. 2013 Nov;38(9):1129-37. doi: 10.1111/apt.12492. Epub 2013 Sep 16.

17.

Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.

Miura M, Kagaya H, Tada H, Sagae Y, Satoh S, Habuchi T, Suzuki T.

Xenobiotica. 2005 May;35(5):479-86.

PMID:
16012079
18.

Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.

Miura M, Kagaya H, Tada H, Uno T, Yasui-Furukori N, Tateishi T, Suzuki T.

Br J Clin Pharmacol. 2006 Mar;61(3):315-20.

19.

Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.

Kim KA, Shon JH, Park JY, Yoon YR, Kim MJ, Yun DH, Kim MK, Cha IJ, Hyun MH, Shin JG.

Clin Pharmacol Ther. 2002 Jul;72(1):90-9.

PMID:
12152007
20.

Supplemental Content

Support Center